Paired box gene 8-peroxisome proliferator-activated receptor-γ fusion protein and loss of phosphatase and tensin homolog synergistically cause thyroid hyperplasia in transgenic mice

Endocrinology

Volumn 150, Issue 11, 2009, Pages 5181-5190

  Diallo Krou, Ericka ^a   Yu, Jingcheng ^a   Colby, Lesley A ^a   Inoki, Ken ^a   Wilkinson, John E ^a   Thomas, Dafydd G ^b   Giordano, Thomas J ^b   Koenig, Ronald J ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; KI 67 ANTIGEN; PAIRED BOX GENE 8 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA FUSION PROTEIN; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RNA; TENSIN; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME PHOSPHORYLATION; GENE DELETION; GENE EXPRESSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID ADENOMA; THYROID CARCINOMA; THYROID HYPERPLASIA; TRANSGENIC MOUSE;

ANIMALS; FEMALE; HUMANS; HYPERPLASIA; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; ONCOGENE PROTEINS, FUSION; PAIRED BOX TRANSCRIPTION FACTORS; PPAR GAMMA; PTEN PHOSPHOHYDROLASE; THYROID GLAND;

EID: 70350328991     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2009-0701     Document Type: Article

References (43)

1. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, Fletcher JA 2000 PAX8-PPARγ1 fusion in oncogene human thyroid carcinoma. Science 289:1357-1360 (Pubitemid 30656054)
2. Macchia PE, Lapi P, Krude H, Pirro MT, Missero C, Chiovato L, Souabni A, Baserga M, Tassi V, Pinchera A, Fenzi G, Grüters A, Busslinger M, Di Lauro R 1998 PAX8 mutations associated with congenital hypothyroidism caused by thyroid dysgenesis. Nat Genet 19:83-86 (Pubitemid 28242030)
3. Mansouri A, Chowdhury K, Gruss P 1998 Follicular cells of the thyroid gland require Pax8 gene function. Nat Genet 19:87-90 (Pubitemid 28242031)
4. Esposito C, Miccadei S, Saiardi A, Civitareale D 1998 PAX 8 activates the enhancer of the human thyroperoxidase gene. Biochem J 331(Pt 1):37-40 (Pubitemid 28163954)
5. Ohno M, Zannini M, Levy O, Carrasco N, di Lauro R 1999 The paired-domain transcription factor Pax8 binds to the upstream enhancer of the rat sodium/iodide symporter gene and participates in both thyroid-specific and cyclic-AMP-dependent transcription. Mol Cell Biol 19:2051-2060 (Pubitemid 29098263)
6. Fabbro D, Pellizzari L, Mercuri F, Tell G, Damante G 1998 Pax-8 protein levels regulate thyroglobulin gene expression. J Mol Endocrinol 21:347-354 (Pubitemid 29005406)
7. Au AY, McBride C, Wilhelm Jr KG, Koenig RJ, Speller B, Cheung L, Messina M, Wentworth J, Tasevski V, Learoyd D, Robinson BG, Clifton-Bligh RJ 2006 PAX8-peroxisome proliferator-activated receptor γ (PPARγ) disrupts normal PAX8 or PPARγ transcriptional function and stimulates follicular thyroid cell growth. Endocrinology 147:367-376 (Pubitemid 43004290)
8. Gregory Powell J, Wang X, Allard BL, Sahin M, Wang XL, Hay ID, Hiddinga HJ, Deshpande SS, Kroll TG, Grebe SK, Eberhardt NL, McIver B 2004 The PAX8/PPARγ fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARγ inhibition. Oncogene 23:3634-3641
9. Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, Spiegelman BM, Singer S 1999 Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 96:3951-3956 (Pubitemid 29169017)
10. Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, de la Chapelle A, Spiegelman BM, Eng C 1999 Loss-of-function mutations in PPARγ associated with human colon cancer. Mol Cell 3:799-804 (Pubitemid 29323058)
11. Giordano TJ, Au AY, Kuick R, Thomas DG, Rhodes DR, Wilhelm Jr KG, Vinco M, Misek DE, Sanders D, Zhu Z, Ciampi R, Hanash S, Chinnaiyan A, Clifton-Bligh RJ, Robinson BG, Nikiforov YE, Koenig RJ 2006 Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. Clin Cancer Res 12:1983-1993
12. Lacroix L, Lazar V, Michiels S, Ripoche H, Dessen P, Talbot M, Caillou B, Levillain JP, Schlumberger M, Bidart JM 2005 Follicular thyroid tumors with the PAX8-PPARγ1 rearrangement display characteristic genetic alterations. Am J Pathol 167:223-231 (Pubitemid 40884783)
13. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C, Parsons R 1997 Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16:64-67
14. Yeager N, Klein-Szanto A, Kimura S, Di Cristofano A 2007 Pten loss in the mouse thyroid causes goiter and follicular adenomas: insights into thyroid function and Cowden disease pathogenesis. Cancer Res 67:959-966 (Pubitemid 46270750)
15. Nagy A, Gertsenstein M, Vintersten K, Behringer R 2003 Manipulating the mouse embryo: a laboratory manual. 3rd ed. New York: Cold Spring Harbor Press
16. Kusakabe T, Kawaguchi A, Kawaguchi R, Feigenbaum L, Kimura S 2004 Thyrocyte-specific expression of Cre recombinase in transgenic mice. Genesis 39:212-216 (Pubitemid 39079520)
17. Lesche R, Groszer M, Gao J, Wang Y, Messing A, Sun H, Liu X, Wu H 2002 Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis 32:148-149 (Pubitemid 34211723)
18. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G, Vasko V, Xing M 2007 Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 13:1161-1170 (Pubitemid 46424056)
19. Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M, Nowill AE, Leslie NR, Cardoso AA, Barata JT 2008 PTEN post-translational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 118: 3762-3774
20. Marques AR, Espadinha C, Catarino AL, Moniz S, Pereira T, Sobrinho LG, Leite V 2002 Expression of PAX8-PPARγ1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 87:3947-3952 (Pubitemid 34879553)
21. Marques AR, Espadinha C, Frias MJ, Roque L, Catarino AL, Sobrinho LG, Leite V 2004 Underexpression of peroxisome proliferator-activated receptor (PPAR)γ in PAX8/PPARγ-negative thyroid tumours. Br J Cancer 91:732-738 (Pubitemid 39141633)
22. Klopper JP, Hays WR, Sharma V, Baumbusch MA, Hershman JM, Haugen BR 2004 Retinoid X receptor-γ and peroxisome proliferator-activated receptor-γ expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Mol Cancer Ther 3:1011-1020 (Pubitemid 39199596)
23. Park JW, Zarnegar R, Kanauchi H, Wong MG, Hyun WC, Ginzinger DG, Lobo M, Cotter P, Duh QY, Clark OH 2005 Troglitazone, the peroxisome proliferator-activated receptor-γ agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid 15:222-231 (Pubitemid 40418689)
24. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR 2008 Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93:4331-4341 (Pubitemid 352789529)
25. Kato Y, Ying H, Zhao L, Furuya F, Araki O, Willingham MC, Cheng SY 2006 PPARγ insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-κ-B signaling pathway. Oncogene 25:2736-2747
26. Lui WO, Zeng L, Rehrmann V, Deshpande S, Tretiakova M, Kaplan EL, Leibiger I, Leibiger B, Enberg U, Höög A, Larsson C, Kroll TG 2008 CREB3L2-PPARγ fusion mutation identifies a thyroid signaling pathway regulated by intramembrane proteolysis. Cancer Res 68:7156-7164
27. Robson EJ, He SJ, Eccles MR 2006 A PANorama of PAX genes in cancer and development. Nat Rev Cancer 6:52-62
28. Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH, Refetoff S, Nikiforov YE, Fagin JA 2005 Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 65:4238-4245 (Pubitemid 40775662)
29. Jhiang SM, Sagartz JE, Tong Q, Parker-Thornburg J, Capen CC, Cho JY, Xing S, Ledent C 1996 Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 137:375-378 (Pubitemid 26005013)
30. Vitagliano D, Portella G, Troncone G, Francione A, Rossi C, Bruno A, Giorgini A, Coluzzi S, Nappi TC, Rothstein JL, Pasquinelli R, Chiappetta G, Terracciano D, Macchia V, Melillo RM, Fusco A, Santoro M 2006 Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas. Oncogene 25:5467-5474 (Pubitemid 44330289)
31. Paes JE, Ringel MD 2008 Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol Metab Clin North Am 37:375-387
32. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ, Sabatini DM 2006 Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCα, but not S6K1. Dev Cell 11:859-871
33. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J, Su B 2006 SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127:125-137 (Pubitemid 44466632)
34. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM 2005 Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098-1101
35. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR, Gout I, Downes CP, Lamb RF 2004 The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 166:213-223 (Pubitemid 38988774)
36. Manning BD, Logsdon MN, Lipovsky AI, Abbott D, Kwiatkowski DJ, Cantley LC 2005 Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev 19:1773-1778 (Pubitemid 41126916)
37. Huang J, Dibble CC, Matsuzaki M, Manning BD 2008 The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol 28:4104-4115 (Pubitemid 351812994)
38. Troussard AA, Mawji NM, Ong C, Mui A, St-Arnaud R, Dedhar S 2003 Conditional knock-out of integrin-linked kinase demonstrates an essential role in protein kinase B/Akt activation. J Biol Chem 278:22374-22378 (Pubitemid 36830287)
39. Han S, Ritzenthaler JD, Zheng Y, Roman J 2008 PPARβ/δ agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression: the involvement of PI3K and NF-κB signals. Am J Physiol Lung Cell Mol Physiol 294:L1238-L1249
40. Suzuki H, Willingham MC, Cheng SY 2002 Mice with a mutation in the thyroid hormone receptor β gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid 12:963-969 (Pubitemid 35404130)
41. Furuya F, Hanover JA, Cheng SY 2006 Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone β receptor. Proc Natl Acad Sci USA 103:1780-1785 (Pubitemid 43228770)
42. Guigon CJ, Zhao L, Willingham MC, Cheng SY 2009 PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer. Oncogene 28:509-517
43. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK 2000 Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407:538-541 (Pubitemid 30746711)